目的 探讨急性冠状动脉综合征（ACS）患者CYP2C19基因多态性对经皮冠状动脉介入治疗（PCI）后服用氯吡格雷血小板抑制率的影响。方法 选择诊断为ACS且进行PCI术的537例患者为研究对象，分析用药后血小板抑制率与CYP2C19基因多态性的相关性。结果 与快代谢者（216例，40.22%）相比，中间代谢者（246例，45.81%）的血小板抑制率明显降低{（44.86±12.36）% vs. （55.77±15.23）%}，差异具有统计学意义（t=8.384，P<0.001）；慢代谢者（75例，13.97%）的血小板抑制率与快代谢者{（36.75±12.77）% vs. （55.77±15.23）%}和中间代谢者{（36.75±12.77）% vs.（44.86±12.36）%}相比，均显著降低，差异具有统计学意义（?t=9.693，?P<0.001；?t=4.932，?P<0.001）。结论 CYP2C19基因多态性与ACS患者行PCI术后服用氯吡格雷的血小板抑制率存在相关性，CYP2C19基因多态性可作为PCI术患者抗血小板用药策略的参考依据。

AIM To investigate the effect of CYP2C19 gene polymorphism of Acute coronary syndrome (ACS) patients who receive PCI surgery on the platelet inhibition rate after taking Clopidogrel. METHODS 537 patients who have been diagnosed as ACS and receiving PCI were included in analysis, and the relevance of platelet inhibition rate and CYP2C19 gene polymorphism was analyzed. RESULTS Compared with extensive metabolism (216 cases, 40.22%), the intermediate metabolism (246 cases, 45.81%) platelet inhibition rate was significantly reduced {(44.86 ± 12.36)% vs. (55.77 ± 15.23)%}, differences was statistically significant (t = 8.384, P <0.001); poor metabolism (75 cases, 13.97%) of platelet inhibition rate was also significantly reduced comparing with extensive metabolism {(36.75 ± 12.77)% vs. (55.77 ± 15.23)%} and intermediate metabolism{(36.75 ± 12.77)% vs. (44.86 ± 12.36)%}, and the difference has statistically significant (?t=9.693, ?P<0.001; ?t=4.932, ?P<0.001, respectively). CONCLUSION There is a significant correlation between CYP2C19 gene polymorphism and platelet inhibition rate in ACS patients who receiving PCI, which can be used as a reference basis for anti-platelet for patients with PCI.

内蒙古自治区高等学校科学研究项目（NJZY17114）